{
    "name": "cytarabine/daunorubicin liposomal",
    "comment": "Rx",
    "other_names": [
        "Vyxeos"
    ],
    "classes": [
        "Antineoplastics",
        "Anthracyclines",
        "Antineoplastics",
        "Antimetabolites"
    ],
    "source": "https://reference.medscape.com/drug/vyxeos-cytarabine-daunorubicin-liposomal-1000185",
    "pregnancy": {
        "common": [
            "Based on data of cytarabine in pregnant females and study results of daunorubicin and cytarabine in animals, embryofetal harm may occur when administered to pregnant females",
            "There are no adequate and well-controlled studies of Vyxeos, daunorubicin, or cytarabine in pregnant females",
            "Advise to avoid becoming pregnant during treatment",
            "If used during pregnancy, or if patient becomes pregnant while taking this drug, apprise patient of the potential harm to a fetus",
            "Verify pregnancy status of females of reproductive potential before initiating treatment"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "Daunorubicin and cytarabine are reproductive and developmental toxicants in multiple species (mice, rats, and/or dogs), starting dose was ~0.02x the exposure in patients at the recommended human dose on a mg/m2 basis"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females and males with female partners of reproductive potential: Use effective contraception during treatment and for at least 6 months after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings of daunorubicin and cytarabine in animals, male fertility may be compromised by treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence or its metabolites in human milk, effects on breastfed infants, or effects on milk production",
            "Advise not to breastfeed during treatment and for at least 2 weeks after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Do not interchange with other daunorubicin- and/or cytarabine -containing products",
                "Vyxeos has different dosage recommendations than daunorubicin, cytarabine, liposomal daunorubicin, and liposomal cytarabine",
                "Do not substitute other preparations of daunorubicin or cytarabine for Vyxeos",
                "Verify drug name and dose prior to preparation and administration to avoid dosing errors"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Serious hypersensitivity to daunorubicin, cytarabine, or any component of the formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not interchange with other daunorubicin- and/or cytarabine- containing products",
                "Serious or fatal hemorrhage events may occur; monitor blood cell counts until recovery and administer platelet transfusion if needed",
                "Reports of fatal hypersensitivity reactions (eg, anaphylactic reactions); monitor for hypersensitivity reactions",
                "Severe local tissue necrosis at extravasation site has been associated with daunorubicin; confirm patency of intravenous access before administration; administer IV only; do not administer IM or SC",
                "May cause embryofetal harm"
            ],
            "specific": [
                {
                    "type": "Copper overload",
                    "description": [
                        "Reconstituted solution contains 5 mg/mL copper gluconate (14% elemental copper)",
                        "Maximum theoretical total exposure of copper for dosing regimen is 106 mg/m",
                        "2",
                        "No clinical experience in patients with Wilson disease or other copper-related metabolic disorders; use only if benefits outweigh risks",
                        "Consult with a hepatologist and nephrologist with expertise in managing acute copper toxicity in treated patients with Wilson’s disease",
                        "Monitor total serum copper, serum nonceruloplasmin bound copper, 24-hr urine copper levels, and serial neuropsychological examinations in these patients",
                        "Discontinue if signs or symptoms of acute copper toxicity occurs"
                    ]
                },
                {
                    "type": "Cardiotoxicity",
                    "description": [
                        "Pre-existing cardiac disease, previous radiotherapy to the mediastinum, or concomitant use of cardiotoxic drugs may increase the risk of daunorubicin induced cardiac toxicity",
                        "Monitor as clinically required; discontinue in patients with impaired cardiac function unless benefit of treatment outweighs the risk",
                        "Not recommended in patients with abnormal left ventricular ejection fraction",
                        "Calculate lifetime cumulative anthracycline exposure before each cycle; total cumulative doses of nonliposomal daunorubicin > 550 mg/m",
                        "2",
                        " have been associated with an increased incidence of drug-induced congestive heart failure; tolerable limit appears lower (400 mg/m",
                        "2",
                        ") in patients who received radiation therapy to the mediastinum",
                        "Not recommended in patients whose lifetime anthracycline exposure has reached the maximum cumulative limit",
                        "Cumulative exposure of daunorubicin",
                        "First induction cycle: Daunorubicin per dose 44 mg/m",
                        "2",
                        " for 3 doses; daunorubicin per cycle 132 m",
                        "2",
                        "Second induction cycle: Daunorubicin per dose 44 mg/m",
                        "2",
                        " for 2 doses; daunorubicin per cycle 88 mg/m",
                        "2",
                        "Each consolidation cycle: Daunorubicin per dose 29 mg/m",
                        "2",
                        " for 2 doses; daunorubicin per cycle 58 mg/m",
                        "2​"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Cardiotoxic agents",
                        "Assess cardiac function more frequently",
                        "Coadministration with cardiotoxic agents may increase the risk of cardiotoxicity",
                        "Hepatoxicity",
                        "Closely monitor hepatic function",
                        "Coadministration with hepatotoxic agents may impair liver function and increase toxicity"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "cytarabine decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "cytarabine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "cytarabine, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cedazuridine",
            "description": {
                "common": "cedazuridine will increase the level or effect of cytarabine by  decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "cytarabine, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "cytarabine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "cytarabine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "cytarabine decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "cytarabine, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of cytarabine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, cytarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tepotinib",
            "description": {
                "common": "tepotinib will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "cytarabine, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "cytarabine, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, daunorubicin liposomal.\nEither increases toxicity of the other by unknown mechanism. Avoid or Use Alternate Drug. Trastuzumab may cause cardiomyopathy. Incidence and severity was highest when used with anthracycline-containing chemotherapy regimens. If possible, avoid anthracycline-based therapy for 7 months after last trastuzumab/hyaluronidase dose. If anthracyclines are used, carefully monitor cardiac function."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, cytarabine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and cytarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "berotralstat will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "cytarabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "cytarabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "cytarabine, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and cytarabine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "cytarabine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Cytarabine may decrease digoxin absorption even several days after stopping chemotherapy. Digoxin capsules and digitoxin do not appear to be affected. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "cytarabine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of daunorubicin liposomal by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "cytarabine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "cytarabine decreases effects of influenza A (H5N1) vaccine by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "cytarabine decreases effects of influenza virus vaccine (H5N1), adjuvanted by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "cytarabine decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, daunorubicin liposomal.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "cytarabine and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, daunorubicin liposomal.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and cytarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "cytarabine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and cytarabine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, cytarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, cytarabine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and cytarabine both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "cytarabine decreases effects of gentamicin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of cytarabine by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "taurine",
            "description": {
                "common": "cytarabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "vitamin A, cytarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, cytarabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hemorrhage",
            "percent": "70"
        },
        {
            "name": "all grades",
            "percent": "68"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "66"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "54"
        },
        {
            "name": "grade",
            "percent": "51"
        },
        {
            "name": "Rash",
            "percent": "47"
        },
        {
            "name": "all grades",
            "percent": "45"
        },
        {
            "name": "Edema",
            "percent": "33"
        },
        {
            "name": "all grades",
            "percent": "33"
        },
        {
            "name": "Nausea",
            "percent": "33"
        },
        {
            "name": "all grades",
            "percent": "32"
        },
        {
            "name": "Diarrhea",
            "percent": "32"
        },
        {
            "name": "colitis",
            "percent": "30"
        },
        {
            "name": "all grades",
            "percent": "29"
        },
        {
            "name": "Abdominal pain",
            "percent": "28"
        },
        {
            "name": "all grades",
            "percent": "26"
        },
        {
            "name": "Cough",
            "percent": "25"
        },
        {
            "name": "all grades",
            "percent": "25"
        },
        {
            "name": "Headache",
            "percent": "24"
        },
        {
            "name": "all grades",
            "percent": "24"
        },
        {
            "name": "Dyspnea",
            "percent": "23"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "23"
        },
        {
            "name": "all grades",
            "percent": "20"
        },
        {
            "name": "Arrhythmia",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "20"
        },
        {
            "name": "Decreased appetite",
            "percent": "20"
        },
        {
            "name": "all grades",
            "percent": "44"
        },
        {
            "name": "Prolonged thrombocytopenia",
            "percent": "38"
        },
        {
            "name": "induction",
            "percent": "18"
        },
        {
            "name": "Pneumonia",
            "percent": "18"
        },
        {
            "name": "excluding fungal",
            "percent": "18"
        },
        {
            "name": "all grades",
            "percent": "18"
        },
        {
            "name": "Sleep disorders",
            "percent": "18"
        },
        {
            "name": "all grades",
            "percent": "17"
        },
        {
            "name": "Prolonged thrombocytopenia",
            "percent": "17"
        },
        {
            "name": "consolidation cycle",
            "percent": "17"
        },
        {
            "name": "Bacteremia",
            "percent": "16"
        },
        {
            "name": "excluding sepsis",
            "percent": "16"
        },
        {
            "name": "all grades",
            "percent": "16"
        },
        {
            "name": "Vomiting",
            "percent": "15"
        },
        {
            "name": "all grades",
            "percent": "14"
        },
        {
            "name": "Chills",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "13"
        },
        {
            "name": "Bacteremia",
            "percent": "11"
        },
        {
            "name": "excluding sepsis",
            "percent": "11"
        },
        {
            "name": "grade",
            "percent": "11"
        },
        {
            "name": "Hypotension",
            "percent": "11"
        },
        {
            "name": "all grades",
            "percent": "11"
        },
        {
            "name": "Pneumonia",
            "percent": "11"
        },
        {
            "name": "excluding fungal",
            "percent": "10"
        },
        {
            "name": "grade",
            "percent": "10"
        },
        {
            "name": "Non conduction cardiotoxicity",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Mucositis",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Fungal infection",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Hypertension",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Hypoxia",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "10"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "3"
        },
        {
            "name": "excluding fungal",
            "percent": "10"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Prolonged neutropenia",
            "percent": "9"
        },
        {
            "name": "induction cycle",
            "percent": "3"
        },
        {
            "name": "Chest pain",
            "percent": "7"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Pyrexia",
            "percent": "7"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Catheter",
            "percent": "5"
        },
        {
            "name": "device",
            "percent": "3"
        },
        {
            "name": "injection site reaction",
            "percent": "5"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Delirium",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Pleural effusion",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Pruritus",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Anxiety",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Hypoxia",
            "percent": "3"
        },
        {
            "name": "grade",
            "percent": "3"
        },
        {
            "name": "Hemorrhoids",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Petechiae",
            "percent": "2"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Renal insufficiency",
            "percent": "2"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Transfusion reactions",
            "percent": "2"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Visual impairment",
            "percent": "1"
        },
        {
            "name": "all grades",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "1"
        },
        {
            "name": "Deafness",
            "percent": "3"
        },
        {
            "name": "Deafness unilateral",
            "percent": "1"
        },
        {
            "name": "Eye conjunctivitis",
            "percent": null
        },
        {
            "name": "Dry eye",
            "percent": null
        },
        {
            "name": "Eye edema",
            "percent": null
        },
        {
            "name": "Eye swelling",
            "percent": null
        },
        {
            "name": "Eye irritation",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Periorbital edema",
            "percent": null
        },
        {
            "name": "Scleral hyperemia",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Hallucinations",
            "percent": null
        },
        {
            "name": "Pneumonitis",
            "percent": null
        },
        {
            "name": "Prolonged neutropenia",
            "percent": null
        },
        {
            "name": "consolidation",
            "percent": null
        },
        {
            "name": "Hemorrhage",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Non conduction cardiotoxicity",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Fungal infection",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Renal insufficiency",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": null
        },
        {
            "name": "excluding fungal",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Delirium",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "colitis",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Muscloskeletal pain",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Pleural effusion",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Transfusion reactions",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "related reactions",
            "percent": null
        }
    ]
}